Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer

NCT07001618 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

162

Enrollment

OTHER

Sponsor class

Conditions

NSCLC (Advanced Non-small Cell Lung Cancer)

Interventions

DRUG: MaaT033 capsule
DRUG: Cemiplimab
DRUG: Cisplatin
DRUG: Carboplatine
DRUG: Pemetrexed (Alimta)
DRUG: Bevacizumab
DRUG: Paclitaxel
DRUG: gemcitabine
DRUG: Docetaxel
DRUG: Vinorelbine i.v. 25 mg/m²
DRUG: Vinorelbine oral

Sponsor

Gustave Roussy, Cancer Campus, Grand Paris

Collaborators

[object Object]
[object Object]